Jasper Therapeutics, Inc. — Director's Dealing 2021

Oct 1, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Jasper Therapeutics, Inc. (JSPR)
CIK: 0001788028
Period of Report: 2021-09-24

Reporting Person: Lis William (Director, Chief Executive Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$0.71	2030-05-31	Common Stock (730850)		Direct
Stock Option (right to buy)	$0.71	2030-09-02	Common Stock (229095)		Direct

Footnotes

F1: 50% of the original number of shares subject to the option were vested as of June 1, 2020, the date of grant; 5% of the original number of shares subject to the option vested on June 21, 2020 and monthly thereafter through and including November 21, 2020; and 1.66% of the original number of shares subject to the option vested on December 21, 2020 and have vested and shall vest monthly thereafter through and including November 21, 2021, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

F2: 1/18th of the original number of shares subject to the option vested on September 3, 2020, and 1/18th of the original number of shares have vested and shall vest monthly thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date.